The article discusses the Amyvid brain scan test developed to help diagnose patients with early-stage Alzheimer's disease as of December 2013. It mentions that although the U.S. Food and Drug Administration (FDA) approved the test in 2012, some doctors are concerned that there are doubts about the role of amyloid in the disease. It says that questions about the value of information provided by the scan have also caused doctors to debate about the timing for an Amyvid test.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados